Statements (146)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
gptkb:Company |
| gptkbp:academic_advisor |
renowned experts
|
| gptkbp:acquired |
Myriad Pharmaceuticals
|
| gptkbp:acquired_by |
gptkb:Invitae_Corporation
|
| gptkbp:acquisition |
gptkb:Certa_Scan
gptkb:Myriad_RBM gptkb:Myriad_Genetic_Laboratories,_Inc. gptkb:Myriad_Women's_Health,_Inc. Cynvenio Biosystems Cure Metrix Myriad Genetics, Inc. (formerly known as Myriad Pharmaceuticals) SOPHi A GENETICS |
| gptkbp:awards |
numerous industry awards
various industry recognitions |
| gptkbp:business_model |
direct-to-consumer testing
|
| gptkbp:ceo |
gptkb:Mark_C._Capone
gptkb:Paul_D._Diaz |
| gptkbp:clinical_laboratories |
CAP accredited
|
| gptkbp:clinical_trial |
ongoing
collaborative studies cancer therapies multiple ongoing |
| gptkbp:collaborates_with |
academic institutions
|
| gptkbp:collaboration |
academic institutions
pharmaceutical companies |
| gptkbp:collaborations |
biopharmaceutical companies
|
| gptkbp:community_engagement |
patient advocacy groups
|
| gptkbp:community_involvement |
research funding
educational outreach various health initiatives patient advocacy programs |
| gptkbp:community_support |
healthcare initiatives
|
| gptkbp:conference |
participates in medical conferences
|
| gptkbp:customer_base |
hospitals and clinics
|
| gptkbp:data_privacy |
committed to protecting data
|
| gptkbp:developed_by |
gptkb:my_Risk_Hereditary_Cancer_test
|
| gptkbp:divisions |
Myriad Genetics, Myriad Women's Health
|
| gptkbp:employees |
approximately 1,000
~1,000 |
| gptkbp:employs |
gptkb:scientists
|
| gptkbp:financial_performance |
growing revenue
|
| gptkbp:focus |
genetic testing
|
| gptkbp:focus_area |
gptkb:neurodegenerative_diseases
oncology personalized medicine cardiovascular health women's health |
| gptkbp:focuses_on |
genetic testing
|
| gptkbp:founded |
gptkb:1991
gptkb:1993 |
| gptkbp:founded_in |
gptkb:1993
|
| gptkbp:founder |
gptkb:Mark_Skolnick
|
| gptkbp:future_plans |
expanding into new markets
|
| gptkbp:grants |
awarded for genetic research
|
| gptkbp:has_collaborations_with |
research institutions
|
| gptkbp:has_developed |
genetic tests for hereditary cancer
|
| gptkbp:has_impact_on |
patient access to genetic information
|
| gptkbp:has_part |
genetic innovation
|
| gptkbp:has_partnerships_with |
pharmaceutical companies
|
| gptkbp:has_patents_on |
genetic sequences
|
| gptkbp:has_research_focus |
cancer genetics
|
| gptkbp:headcount |
growing
|
| gptkbp:headquartered_in |
gptkb:Salt_Lake_City,_Utah
|
| gptkbp:headquarters |
gptkb:Salt_Lake_City,_Utah
|
| gptkbp:healthcare |
genetic counseling
multiple tests |
| https://www.w3.org/2000/01/rdf-schema#label |
Myriad Genetics, Inc.
|
| gptkbp:impact |
research funding
healthcare policies biotechnology regulations genetic testing industry patient access to genetic information |
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:innovation |
genetic testing technologies
|
| gptkbp:invention |
over 500
|
| gptkbp:investment |
various venture capital firms
in R& D |
| gptkbp:ipo |
gptkb:2013
|
| gptkbp:is_a |
gptkb:biotechnology
|
| gptkbp:is_a_platform_for |
proprietary algorithms
|
| gptkbp:is_challenged_by |
legal organizations
|
| gptkbp:is_involved_in |
patient advocacy groups
clinical research genetic patenting debates |
| gptkbp:is_known_for |
patent litigation
|
| gptkbp:is_part_of |
genomics sector
|
| gptkbp:is_recognized_by |
medical community
|
| gptkbp:is_recognized_for |
innovative testing
|
| gptkbp:is_subject_to |
FDA regulations
patent law changes |
| gptkbp:key_people |
gptkb:Mark_C._Capone
|
| gptkbp:known_for |
BRCA1 and BRCA2 gene patents
|
| gptkbp:legal_issue |
patent disputes
|
| gptkbp:market_cap |
$1.5 billion (2021)
|
| gptkbp:market_position |
global
|
| gptkbp:mission |
improving patient outcomes
to improve patient care through genetic testing |
| gptkbp:notable_case |
Myriad Genetics, Inc. v. Association for Molecular Pathology
|
| gptkbp:notable_products |
BRCA1 and BRCA2 gene tests
|
| gptkbp:offers |
genetic counseling
|
| gptkbp:operates_in |
biotechnology industry
|
| gptkbp:partnership |
gptkb:University_of_Utah
gptkb:Cigna gptkb:Blue_Cross_Blue_Shield gptkb:United_Healthcare gptkb:national_flag gptkb:Aetna |
| gptkbp:partnerships |
academic institutions
pharmaceutical companies with insurers |
| gptkbp:patient_outreach |
gptkb:educational_programs
|
| gptkbp:previously_known_as |
Myriad Pharmaceuticals
|
| gptkbp:products |
genetic testing
|
| gptkbp:provides |
laboratory services
|
| gptkbp:provides_guidance_on |
influences guidelines
|
| gptkbp:publications |
numerous scientific papers
|
| gptkbp:regulatory_compliance |
meets FDA standards
|
| gptkbp:research_focus |
gptkb:neurodegenerative_diseases
biomarker discovery genomic medicine precision medicine cancer genetics genetic variants cardiovascular genetics |
| gptkbp:revenue |
$1 billion (2020)
$200 million (2020) genetic tests |
| gptkbp:services |
molecular diagnostics
genetic counseling clinical laboratory services |
| gptkbp:services_provided |
healthcare providers
risk assessment |
| gptkbp:side_effect |
improving diagnosis
|
| gptkbp:social_responsibility |
health equity initiatives
|
| gptkbp:stock_symbol |
gptkb:MYGN
|
| gptkbp:strategic_goals |
expanding test offerings
|
| gptkbp:subsidiary |
gptkb:Myriad_Genetic_Laboratories
gptkb:Myriad_Neuroscience gptkb:Myriad_Women's_Health gptkb:Myriad_Oncology |
| gptkbp:technology |
next-generation sequencing
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:vision |
to be the world leader in genetic testing
transforming healthcare through genetics |
| gptkbp:website |
myriad.com
|